肺动脉高压治疗药物综述。
A review of therapeutic agents for the management of pulmonary arterial hypertension.
作者信息
Hahn Stella S, Makaryus Mina, Talwar Arunabh, Narasimhan Mangala, Zaidi Gulrukh
机构信息
Northwell Health Division of Pulmonary Critical Care and Sleep Medicine, 410 Lakeville Road, Suite 107, New Hyde Park, NY 11042, USA.
出版信息
Ther Adv Respir Dis. 2017 Jan;11(1):46-63. doi: 10.1177/1753465816665289. Epub 2016 Sep 19.
Abstract
Pulmonary arterial hypertension (PAH) is an uncommon, progressive and life threatening disease characterized by a proliferative vasculopathy of the small muscular pulmonary arterioles resulting in elevated pulmonary vascular resistance and eventually right ventricular failure. An increasing understanding of the pathobiology of PAH and its natural history has led to the development of numerous targeted therapies. Despite these advances there is significant progression of disease and the survival rate remains low. This article reviews the agents currently available for the medical management of PAH.
摘要
肺动脉高压（PAH）是一种罕见、进行性且危及生命的疾病，其特征是小肌性肺小动脉发生增殖性血管病变，导致肺血管阻力升高，最终引发右心室衰竭。对PAH病理生物学及其自然史的认识不断加深，促使了众多靶向治疗方法的发展。尽管取得了这些进展，但疾病仍有显著进展，生存率仍然很低。本文综述了目前可用于PAH药物治疗的药物。
相似文献
1
A review of therapeutic agents for the management of pulmonary arterial hypertension.肺动脉高压治疗药物综述。
Ther Adv Respir Dis. 2017 Jan;11(1):46-63. doi: 10.1177/1753465816665289. Epub 2016 Sep 19.
2
Targeted therapies in pulmonary arterial hypertension.肺动脉高压的靶向治疗。
Pharmacol Ther. 2014 Feb;141(2):172-91. doi: 10.1016/j.pharmthera.2013.10.002. Epub 2013 Oct 14.
3
Combination therapy in the management of pulmonary arterial hypertension.肺动脉高压管理中的联合治疗
Int J Clin Pract Suppl. 2013 May(179):13-23. doi: 10.1111/ijcp.12136.
4
The pharmacological treatment of pulmonary arterial hypertension.肺动脉高压的药物治疗。
Pharmacol Rev. 2012 Jul;64(3):583-620. doi: 10.1124/pr.111.005587. Epub 2012 Jun 1.
5
Pulmonary arterial hypertension: a review in pharmacotherapy.肺动脉高压：药物治疗综述
Cardiol Rev. 2015 Jan-Feb;23(1):33-51. doi: 10.1097/CRD.0000000000000042.
6
Novel strategies for treatment of pulmonary arterial hypertension.治疗肺动脉高压的新策略。
Postepy Hig Med Dosw (Online). 2017 Jul 11;71(0):577-588. doi: 10.5604/01.3001.0010.3838.
7
Current management of pulmonary arterial hypertension.肺动脉高压的当前管理
Swiss Med Wkly. 2016 May 31;146:w14305. doi: 10.4414/smw.2016.14305. eCollection 2016.
8
[Novel concepts in the pathobiology of pulmonary arterial hypertension].[肺动脉高压病理生物学的新概念]
Dtsch Med Wochenschr. 2008 Oct;133 Suppl 6:S167-9. doi: 10.1055/s-0028-1091229. Epub 2008 Sep 23.
9
Pulmonary arterial hypertension: a current review of pharmacological management.肺动脉高压：药物治疗现状综述
Pneumonol Alergol Pol. 2016;84(1):47-61. doi: 10.5603/PiAP.a2015.0084. Epub 2015 Dec 23.
10
Pulmonary Arterial Hypertension: Pathophysiology and Treatment.肺动脉高压：病理生理学与治疗
Diseases. 2018 May 16;6(2):38. doi: 10.3390/diseases6020038.
引用本文的文献
1
Activation of Autophagy Induces Monocrotaline-Induced Pulmonary Arterial Hypertension by FOXM1-Mediated FAK Phosphorylation.自噬的激活通过 FOXM1 介导的 FAK 磷酸化诱导单硝酸异山梨酯诱导的肺动脉高压。
Lung. 2022 Oct;200(5):619-631. doi: 10.1007/s00408-022-00569-4. Epub 2022 Sep 15.
2
Autophagy and pulmonary disease.自噬与肺部疾病。
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619890538. doi: 10.1177/1753466619890538.
3
Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.将吡格列酮（一种过氧化物酶体增殖物激活受体γ激动剂和口服抗糖尿病药物）重新用于治疗肺动脉高压的吸入制剂。
J Control Release. 2018 Jun 28;280:113-123. doi: 10.1016/j.jconrel.2018.04.049. Epub 2018 Apr 30.
本文引用的文献
1
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.从波生坦（全可利®）到马昔腾坦（傲朴舒®）：药物化学视角
Bioorg Med Chem Lett. 2016 Aug 1;26(15):3381-94. doi: 10.1016/j.bmcl.2016.06.014. Epub 2016 Jun 10.
2
Endothelin.内皮素
Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833.
3
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.2015年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):177. doi: 10.1016/j.rec.2016.01.002.
4
[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].[2015年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南]
Kardiol Pol. 2015;73(12):1127-206. doi: 10.5603/KP.2015.0242.
5
Selexipag for the Treatment of Pulmonary Arterial Hypertension.塞乐西帕用于肺动脉高压的治疗。
N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.
6
Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge.肺动脉高压患者的抗凝治疗：当前知识的更新。
J Heart Lung Transplant. 2016 Feb;35(2):151-64. doi: 10.1016/j.healun.2015.10.002. Epub 2015 Oct 9.
7
Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).在评估肺动脉高压（PAH）疾病早期和长期管理的注册研究（REVEAL）中，华法林治疗对PAH患者生存的影响
Circulation. 2015 Dec 22;132(25):2403-11. doi: 10.1161/CIRCULATIONAHA.115.018435. Epub 2015 Oct 28.
8
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。
N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.
9
The molecular targets of approved treatments for pulmonary arterial hypertension.肺动脉高压已获批治疗方法的分子靶点。
Thorax. 2016 Jan;71(1):73-83. doi: 10.1136/thoraxjnl-2015-207170. Epub 2015 Jul 28.
10
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.波生坦联合西地那非治疗肺动脉高压患者。
Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.
Zotero 插件